Drug intelligence / Profile preview

PROLUNG

Development stage: Discontinued
Lead developer: The University of Hong Kong
Administration: Oral

Overview

**PROLUNG** is an investigational traditional Chinese herbal granule formula evaluated for idiopathic pulmonary fibrosis. The formula contains nine botanical ingredients: Huang Qi, Dan Shen, Jiang Huang, Yin Xing, Mai Men Dong, Bai He, Jin Yin Hua, Zi Su Ye, and Yin Yang Huo. It was administered orally in a terminated open-label clinical study intended to assess changes in forced vital capacity, respiratory symptoms, and quality of life in idiopathic pulmonary fibrosis. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03274544))

Other names: Prolung

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on PROLUNG.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PROLUNG.

Explore the full profile